Click on this link for a message from our sponsor … Three major areas reflecting government policy are compounding investors’ apprehensions. •Regulatory risk at the U.S. Food and Drug Administration. A 2011 report from the California Healthcare Institute and Boston … Continue reading →
Categories: Ideas For Surgery News |
Tags: 2012 California Biomedical Industry Report , accelerated investments to serve the emerging markets , accelerating globalization , Access to capital , acquisition of technologies , acroMIS Consulting , acromis implementation and development , address patients’ need , address the high risk , adoption of austerity measures , advantageous position , adverse impact on technology , age-related disease , angel investors , around the globe , availability of capital to fund future innovation , BayBio , biggest long-term opportunity , Biomedical Access to Capital , biomedical cluster , biomedical company CEOs , biomedical innovation , biotechnology , Boston Consulting Group , burdensome and uncertain regulatory environment , California Biomedical Industry 2012 Report , California companies are adaptive and resourceful , California Healthcare Institute , California’s biomedical industry , Candidates in queue , CE Mark trial of the next-generation , challenging environment , CHI-California Healthcare Institute , choosing the right delivery method , clinical value , commercialize medtech , comparative effectiveness data CED , competitive landscape is likely to change , compounding investors’ apprehensions , Congress , considered as a first line therapy , constitutional challenges to healthcare reform legislation , constrained coverage and payment for innovative products , constrained healthcare budgets , corporate partnerships as a source of financing , corporate venture capital as a finance source , Corporate venture funding , Cost vs Value , cost-effective solutions , countries with more certain regulatory pathways , coverage and reimbursement issues are extremely important , critical decision factor , current global economic situation , cyclical problem of depressed macroeconomic conditions , dealing with high risk complications , declining performance at the FDA , declining procedure volume , delay a research or development project , deliver value to the overall healthcare system , delivered through two approaches , delivering better economic value , demonstrate the economic value at both the provider and payer levels , develop specific plans to accelerate our global growth , devices approved for procedures , devices are priced at a hefty premium , diagnostics or medical equipment , disease foundations/non-governmental organizations , disruptive business models , each of the major emerging markets , easier access to capital , economic downturn , economic potential of this specialized , emerging markets , engaging primarily with the physician , enrollment in the pilot study , establishment of healthcare insurance exchanges , evaluated the merits of our products solely on the clinical value , Evolving Market , expanding insights into these markets , expanding markets , factors have discouraged investments in biotech and device startups , FDA has the best regulatory approval process in the world , federal efforts to contain the escalation of Medicare spending , Findings of the CEO Survey , first mover advantage , focus on emerging markets , force the players to increasingly compete on price , forced to look for other solutions , Forty-four percent of biomedical CEOs surveyed said they will look to licensing agreements , global growth goals , global leadership position , global P&L responsibility , government grants , government initiatives , great expansion of Medicaid to cover the uninsured , growth opportunity for our industry , Haio Fauser is a local market expert in each of the geographic regions , high surgical risk , Implantable medical devices IMD , Implementation , Implementation of the Affordable Care Act , improving our ability to attract investment and grow , In the face of these challenges , in the OUS market , inconsistent communications , increased pressure in utilization , increasing pressure on drug and device margins , Independent Medicare Payment Advisory Board , innovation and state-of-the-art medical technology , innovative technologies , issues being discussed throughout the biomedical industry by executives , key opinion leader KOL , Lack of funding , lack of innovation and productivity , less invasive treatment , licensing agreements , looking beyond California’s and our nation’s borders , maintain the high standards of safety and effectiveness , major California venture capital firms , many patients with age working against them , market in Europe , Medical devices , medical devices companies , meet the urgent need of patients , meeting the needs of the billions of people in emerging markets , moved out of investing in life sciences companies , multinational , myriad of complications , nascent technologies , necessity of the procedures to be performed in specialized centers , new law being implemented with direct consequences for the biomedical industry , new taxes on drug and devices , noninvasive , onditions , Optimize Innovation And Accelerate Globalization , outside the US OUS , Outside The USA (OUS) Global Markets Amid Soft US Sales , overt risk , partnerships , pharmaceuticals , physicians may have to perform 30 cases before they attain the desired level of proficiency , physicians’ learning curve , pivotal trial , prevailing economic uncertainty , principle investigator , products in clinical development , progressive , project delays cited by private company CEOs , proper selection of patients , providing expertise. early clinical evidence , PwC , raising concerns about coverage and payment for medical technologies , recent launches , recreate the ecosystem that has made the US the leading biomedical region , regions with financial incentives , regions with financial incentives and easier access to capital , Regulatory Environment will Determine R&D Productivity , regulatory framework that is based on consistency , Regulatory risk at the US Food and Drug Administration , reimbursement pressure , representatives on their staff from each region , restructuring initiatives , review our businesses , scheduled for completion , seeking diverse funding sources , sharply reduced their asset allocations , slower growth of US markets , snapshot of the biomedical industry in California , solutions that deliver better economic value , source of funding to the industry , state-of-the-art procedure , strong and collaborative partnership between our business , sustainable growth , targeting a limited launch , tax incentives for innovation , Team work , Technological innovations , The CEO Survey , the continuing healthcare cost crunch , the current FDA regulatory approval process has slowed the growth , the current trajectory of rising healthcare costs is unsustainable , the future of global economic recovery , the investment of corporate funds into external endeavors , the standard of care , threats to the biomedical industry’s growth , three major areas reflecting government policy , to countries with more certain regulatory pathways , To Improve Execution , training of the physicians and staff is significant , unclear standards for what clinical data are necessary for product approval , Under development , unexplained regulatory delays , unfavorable reimbursement decision from the CMS , unsuitable for this open surgery , Value-based health care , we must prioritize our investment , widespread economic uncertainty , Widespread rollout , Working collaboratively with other stakeholders |
Permalink
